secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0000078003-25-000111
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q1 revenues $13.7B (-8% YoY), adjusted EPS $0.92 (+12%); reaffirms FY2025 guidance
--------------------------------------------------------------------------------

- Q1 revenues $13.7B, down 8% YoY; reported diluted EPS $0.52 (down 5%), adjusted diluted EPS $0.92 (up 12%).
- Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00, with no share buybacks anticipated.
- Expands cost realignment: additional $1.2B net savings by 2027 (SI&A focus) plus $500M R&D reinvestment by 2026; one-time costs $1.6B and $600M respectively.
- Paxlovid revenue fell $1.5B operationally (75% drop); Vyndaqel family grew 33% operationally; Comirnaty up 62% operationally.
- Paid $2.4B in cash dividends ($0.43/shr) in Q1; gross leverage below previously stated target; $3.3B remaining buyback authority.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000111/0000078003-25-000111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000111/pfe-20250429.htm
  HTML page:      https://secwatch.observer/filing/0000078003-25-000111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer